Answers are grounded in this paper and cite their sources.
The findings suggest that dupilumab may reduce severe exacerbations and OCS use in patients with SA better than omalizumab, benralizumab and mepolizumab in European real-world settings.
No takes yet. Share an insight, caveat, or question.
Canonica et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: